Home › Funds › BlackRock › iShares Biotechnology ETF
Fund family: BlackRock · Filed by iSHARES TRUST (CIK 1100663) · SEC series S000004350
Ticker: IBB (C000012080)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,712 with, 10 against, 31 abstentions (not counted as with management); 11 items carried no recommendation; 1 split votes are in neither count. Shareholder proposals: 0 FOR, 6 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as BlackRock’s manager page (1,606,521 ballot items across 392 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | BlackRock | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 92.4% | 1,663 | 93.6% | 1,355,861 |
| Backed environmental and social shareholder proposals at US companies | n/a | 1 | 5.5% | 6,306 |
Each ballot item this fund voted is set against the votes of the other BlackRock funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most BlackRock funds on 3 items (0.2% of the 1,425 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most BlackRock funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| BIONTECH SE | 2026-05-15 | Elections to the Supervisory Board: Prof. Dr. Iris Loew-Friedrich | Against | FOR — 6 of 8 BlackRock funds | Against | — |
| BIONTECH SE | 2026-05-15 | Elections to the Supervisory Board: Prof. Dr. Rudolf Staudigl | Against | FOR — 6 of 8 BlackRock funds | Against | — |
| ZAI LAB LTD | 2026-06-17 | THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement, is hereby approved. | For | AGAINST — 2 of 3 BlackRock funds | For | — |
Download all 3 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 79.3% of this fund’s 1,753 such votes could be given a sector; the other 363 (20.7%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 1,317 | 6 | 0.5% |
| Industrials | 63 | 0 | 0.0% |
| Technology | 10 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 987 | 0 |
| Audit-related | 251 | 0 |
| Say-on-Pay | 235 | 0 |
| Compensation | 125 | 4 |
| Corporate Governance | 89 | 3 |
| Capital Structure | 80 | 0 |
| Extraordinary Transactions | 13 | 0 |
| Shareholder Rights and Defenses | 9 | 2 |
| Other Social Issues | 3 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| GILEAD SCIENCES, INC. | April 30, 2026 | $918M | 15 | 3 |
| AMGEN INC. | May 19, 2026 | $911M | 15 | 1 |
| VERTEX PHARMACEUTICALS INCORPORATED | May 13, 2026 | $829M | 15 | 1 |
| REGENERON PHARMACEUTICALS, INC. | June 12, 2026 | $725M | 7 | 0 |
| MODERNA, INC. | November 12, 2025 | $431M | 2 | 0 |
| MODERNA, INC. | May 6, 2026 | $298M | 5 | 0 |
| NATERA, INC. | June 11, 2026 | $284M | 8 | 0 |
| BIOGEN INC. | June 9, 2026 | $273M | 12 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| April 30, 2026 | GILEAD SCIENCES, INC. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | GILEAD SCIENCES, INC. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 19, 2026 | AMGEN INC. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| May 13, 2026 | VERTEX PHARMACEUTICALS INCORPORATED | Shareholder Proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
| May 15, 2026 | MEDPACE HOLDINGS, INC. | Stockholder proposal regarding giving shareholders an ability to call for a special shareholder meeting, if properly presented at the meeting. Shareholder proposal | Against | For |
| June 25, 2026 | CELLECTIS S.A. | delegation of authority to be granted to the Board of Directors to proceed with an increase in the_x000D_ share capital, the subscription of which would be reserved for the members of a company savings_x000D_ plan established pursuant to Articles L. 3332-1 et seq. of the Labor Code. | For | Against |
| November 27, 2025 | IMMUTEP LTD | Approval of Grant of Performance Rights to Mr Pete Meyers | For | Against |
| November 27, 2025 | IMMUTEP LTD | Approval of Grant of Performance Rights to Dr Russell Howard | For | Against |
Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.
1,792 ballot items at 254 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, iShares Biotechnology ETF (IBB) voted at 254 shareholder meetings of 245 companies, on 1,792 ballot items in all. Where management made a recommendation, the fund followed it on 97.7% of the items and voted against it 10 times. Its most frequent area of disagreement was compensation (4 of its votes against management). It voted on 6 shareholder proposals. It voted FOR the board's own proposals less often than BlackRock's funds as a whole (92.4% against 93.6%). It voted differently from most BlackRock funds on 3 items. 1 of its meetings was contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of BlackRock’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.